Amphastar Pharmaceuticals (AMPH) Cash from Operations (2013 - 2026)

Amphastar Pharmaceuticals has reported Cash from Operations for 14 years, with the latest figure at $51.3 million in Q2 2026.

• On a quarterly basis, Cash from Operations rose 44.2% year-over-year to $51.3 million in Q2 2026; TTM through Jun 2026 was $184.6 million, a 15.63% increase from a year earlier, with the FY2025 full-year figure at $156.1 million, down 26.84% from the prior year.
• Cash from Operations was $51.3 million for Q2 2026 at Amphastar Pharmaceuticals, up from $47.8 million in the prior quarter.
• The five-year high for Cash from Operations was $69.1 million in Q2 2024, with the low at $2.8 million in Q2 2022.
• Average Cash from Operations over 5 years is $41.2 million, with a median of $44.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations slumped 91.25% in 2022, then jumped 1851.08% in 2023.
• Over 5 years, Cash from Operations stood at $15.2 million in 2022, then surged by 56.73% to $23.9 million in 2023, then advanced by 21.62% to $29.0 million in 2024, then climbed by 13.23% to $32.9 million in 2025, then jumped by 56.18% to $51.3 million in 2026.
• The last three Cash from Operations figures came in at $51.3 million (Q2 2026), $47.8 million (Q1 2026), and $32.9 million (Q4 2025), per Business Quant data.